en.Wedoany.com Reported - UK fusion technology company Astral Systems has recently completed a £23 million Series A funding round, equivalent to approximately €26 million or $30 million. The company stated that the funds will be used to advance the near-term commercial applications of its Multistate Fusion (MSF) technology and support the full-load operation of multiple next-generation compact fusion reactors by the end of 2026.
This funding round was led by UK venture capital firm Mercia Ventures, with participation from tech investment institutions such as Tees River, Daphni, and Blast Club, while existing investors Speedinvest and Playfair continued to follow on. Following the completion of the funding round, Astral Systems' cumulative funding has exceeded £28 million.
Headquartered in Bristol, UK, Astral Systems was co-founded in 2023 by University of Bristol researcher Tom Wallace-Smith and others. The company claims that its proprietary MSF technology can be used to produce critical medical radioisotopes, with the goal of bringing related products to market by early 2027, while scaling up production of modular MSF reactors and continuing fusion technology research.
The company stated that the supply chain for medical radioisotopes has long been fragile, with global shortages occurring multiple times, affecting cancer diagnosis and treatment. Recent shortages have been primarily linked to temporary declines in the production of molybdenum-99, which can be used to generate technetium-99m, a commonly used radioisotope in medical diagnostics.
Astral Systems previously stated that its compact MSF reactor prototype is small enough to fit on a desktop and has been tested at its UK facility, with fusion performance verified by external independent personnel. The company envisions building regional radioisotope factories in multiple locations across the UK and globally, using small fusion reactors to produce isotopes locally, thereby meeting medical needs in a more flexible manner. Wallace-Smith once noted that compared to building a new nuclear power plant costing approximately £400 million, producing radioisotopes in small facilities near hospitals could cost around £1 million to construct.
Currently, Astral Systems is building new facilities at the former Berkeley nuclear power station site. The company also stated that it has established three commercial fusion facilities and generated over £3 million in revenue through research contracts utilizing MSF technology. Moving forward, Astral Systems will focus on advancing the production of actinium-225 and lead-212, two radioisotopes considered significant for new cancer treatments.
This article is compiled by Wedoany. AI citations must indicate the source "Wedoany". For any copyright issues or other concerns, please notify us promptly, and we will revise or delete the content accordingly. Email: news@wedoany.com
